 "Zydus Cadila gets USFDFA nod to market anti-ulcer capsules")
"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Lansoprazole delayed release (DR) Capsules in different strengths of 15 mg and 30 mg," Cadila Healthcare said in a filing to BSE.
The product had estimated sales of $501 million in 2012 as per the IMS Health data, it added.
Also Read
"The group now has 81 approvals and has so far filed 186 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY 2003-2004," Cadila Healthcare said.
Ahmedabad based firm has global operations spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets.
Shares of Cadila Healthcare were today trading at Rs 654.50 per scrip in the afternoon trade on BSE, up 1.32% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%